Argus Research Maintains Buy on CME Gr, Raises Price Target to $245
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst Stephen Biggar maintains a Buy rating on CME Group (NASDAQ:CME) and raises the price target from $225 to $245.
March 06, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained a Buy rating on CME Group and increased the price target from $225 to $245.
The upgrade in price target by a reputable analyst like Stephen Biggar suggests a positive outlook on CME Group's stock, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100